Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement advertising bill

This article was originally published in The Tan Sheet

Executive Summary

Legislation that would allow the same claims permitted in dietary supplement product labeling to appear in consumer advertising introduced by Sen. Michael Crapo (R-Idaho) Oct. 19. The Dietary Supplement Fairness in Labeling and Advertising Act (S 1749) is similar to the bill Crapo introduced last session while a member of the House (1"The Tan Sheet" Oct. 5, 1998, p. 8). The new version, however, also would make FDA rescind its April 29 proposed rule on what constitutes an acceptable structure/function claim. In floor comments made when introducing the bill, Crapo stated that, with the proposal, FDA was "asserting responsibilities beyond congressional intent." The bill has been referred to the Senate Health, Education, Labor & Pensions Committee

You may also be interested in...

Structure/Function Claims In Ads Would Be Allowed Under House Bill

A bill proposing structure/function claims deemed acceptable for dietary supplement labeling also be allowable for dietary supplement advertising was introduced Sept. 16 on the House floor by Rep. Michael Crapo (R-Idaho).

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts